Free Trial
NASDAQ:DVAX

Dynavax Technologies (DVAX) Stock Price, News & Analysis

Dynavax Technologies logo
$11.06 -0.13 (-1.16%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$11.44 +0.39 (+3.48%)
As of 08/7/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Dynavax Technologies Stock (NASDAQ:DVAX)

Key Stats

Today's Range
$10.94
$11.30
50-Day Range
$9.77
$11.36
52-Week Range
$9.22
$14.63
Volume
1.62 million shs
Average Volume
1.23 million shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00
Consensus Rating
Moderate Buy

Company Overview

Dynavax Technologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

DVAX MarketRank™: 

Dynavax Technologies scored higher than 86% of companies evaluated by MarketBeat, and ranked 146th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Dynavax Technologies has received no research coverage in the past 90 days.

  • Read more about Dynavax Technologies' stock forecast and price target.
  • Earnings Growth

    Earnings for Dynavax Technologies are expected to grow by 53.13% in the coming year, from $0.32 to $0.49 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dynavax Technologies is -21.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dynavax Technologies is -21.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dynavax Technologies has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Dynavax Technologies' valuation and earnings.
  • Percentage of Shares Shorted

    13.25% of the float of Dynavax Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Dynavax Technologies has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

  • Dividend Yield

    Dynavax Technologies does not currently pay a dividend.

  • Dividend Growth

    Dynavax Technologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.25% of the float of Dynavax Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Dynavax Technologies has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

  • News Sentiment

    Dynavax Technologies has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Dynavax Technologies this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    2 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dynavax Technologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.98% of the stock of Dynavax Technologies is held by insiders.

  • Percentage Held by Institutions

    96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dynavax Technologies' insider trading history.
Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
Dynavax (DVAX) Q2 Revenue Jumps 29%
Dynavax Reports Second Quarter 2025 Financial Results
Dynavax Technologies (DVAX) to Release Earnings on Thursday
Dynavax Technologies Corporation (DVAX) - Yahoo Finance
See More Headlines

DVAX Stock Analysis - Frequently Asked Questions

Dynavax Technologies' stock was trading at $12.77 at the start of the year. Since then, DVAX stock has decreased by 13.4% and is now trading at $11.06.

Dynavax Technologies Corporation (NASDAQ:DVAX) issued its quarterly earnings data on Thursday, August, 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 20.39% and a positive trailing twelve-month return on equity of 3.59%.
Read the conference call transcript
.

Top institutional investors of Dynavax Technologies include Chicago Capital LLC (4.35%), Blair William & Co. IL (1.90%), Nordea Investment Management AB (0.65%) and Bank of New York Mellon Corp (0.58%). Insiders that own company stock include Andrew A F Hack, Ryan Spencer, Robert Janssen, Francis Cano, David F Novack and Justin Burgess.
View institutional ownership trends
.

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/07/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DVAX
CIK
1029142
Employees
350
Year Founded
1996

Price Target and Rating

High Price Target
$31.00
Low Price Target
$10.00
Potential Upside/Downside
+117.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
34.56
P/E Growth
N/A
Net Income
$27.31 million
Net Margins
-20.39%
Pretax Margin
-18.85%
Return on Equity
3.59%
Return on Assets
2.20%

Debt

Debt-to-Equity Ratio
0.49
Current Ratio
11.93
Quick Ratio
10.84

Sales & Book Value

Annual Sales
$277.25 million
Price / Sales
4.79
Cash Flow
$0.16 per share
Price / Cash Flow
70.67
Book Value
$4.54 per share
Price / Book
2.44

Miscellaneous

Outstanding Shares
120,080,000
Free Float
116,503,000
Market Cap
$1.33 billion
Optionable
Optionable
Beta
1.09

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:DVAX) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners